On October 22, 2026, the U.S. Treasury Department proposed adding biotechnology to the list of Chinese sectors in which American capital may no longer invest. The proposal was framed as a national security measure. It was reported as another front in the technological competition between the two countries.
Six days later, AstraZeneca, Bristol Myers Squibb, and Roche were still buying the rights to Chinese drugs. The Treasury's fact sheet said explicitly that licensing deals were not off limits.
The exemption was not a concession to Beijing. It was a recognition of something the American pharmaceutical industry has been saying with increasing urgency: it cannot replace the Chinese pipeline, and it cannot afford to try.
The Numbers Behind the Exemption
Through October 8, 2026, overseas licensing agreements involving Chinese pharmaceutical and biotechnology companies reached a combined potential value of $139.4 billion, according to data from PharmCube. That figure surpassed the $138.8 billion recorded for all of 2025.
Upfront payments, the cash that changes hands at signing before any milestone is reached, reached a record level in the first three quarters of 2026, according to PharmCube's data, already above the full-year 2025 total.
The headline numbers are large. The composition is more revealing.
In the first three quarters of 2026, among global licensing and asset-purchase deals signed by pharmaceutical companies with a market capitalization of at least $50 billion, where the upfront payment was at least $50 million, Chinese-origin assets accounted for approximately half of the deals and roughly two-thirds of the upfront dollars, according to PharmCube data. In 2025, those figures were 39 percent and 36 percent. The shift is not incremental. It is a change in where the largest drugmakers source their pipelines.
Chinese companies accounted for a majority of the world's ten largest pharmaceutical deals in the first half of 2026, according to an analysis by the Korea Biotechnology Industry Organization citing a Deloitte China report. The largest was AstraZeneca's agreement with CSPC Pharmaceutical Group in January, worth up to $18.5 billion, with $1.2 billion paid upfront. In May, Bristol Myers Squibb signed a deal with Jiangsu Hengrui Pharmaceuticals worth up to $15.2 billion, with $600 million upfront. In October, Roche agreed to pay Hansoh Pharmaceutical up to $15.5 billion for a portfolio of antibody-drug conjugates, with $400 million upfront.
Those three deals alone account for nearly $50 billion in headline value. The upfront cash — roughly $2.2 billion across the three — is the part that matters for the Chinese companies' balance sheets.
What Washington Actually Did
The Treasury proposal was not designed to stop licensing. It was designed to stop ownership.
The draft rules for the Comprehensive Outbound Investment National Security Act would restrict American capital from financing Chinese biotechnology companies. Equity investments, joint ventures, and the NewCo model — in which American investors create a new company around a Chinese asset and take an ownership stake — would face greater scrutiny. The public comment period runs through December 7, and the final rule is expected by March 13, 2027.
Licensing deals were explicitly carved out. The Treasury's fact sheet stated that licensing agreements were not covered by the proposed restrictions. A Treasury official confirmed that licensing deals are exempt. The Biotechnology Innovation Organization, the industry's main U.S. trade group, had argued against sweeping restrictions. Its CEO, John Crowley, put the position bluntly: "We cannot restrict our way to success."
The exemption reflected a calculation that the American pharmaceutical industry could not absorb the alternative. The industry is facing a patent cliff: a wave of blockbuster drugs losing exclusivity in the late 2020s, with revenue losses that must be replaced by new products. The Chinese pipeline is one of the few sources of late-stage assets large enough to fill the gap.
Why the Pipeline Cannot Be Replaced
The Chinese biotech pipeline is not a marginal supplier. It is roughly 30 percent of the global innovative drug pipeline, according to data from China's National Medical Products Administration.
The reason is speed and cost. A Phase I clinical trial in China runs about seven months, against 17 months or more in the United States. The cost is 32 to 52 percent lower, according to GlobalData analysis, because patient recruitment is faster and the first-in-human review process is shorter. For a drugmaker facing a patent cliff, a seven-month head start on a Phase I trial is worth more than a marginal difference in licensing cost.
AstraZeneca, AbbVie, and Pfizer have each signed multibillion-dollar deals for Chinese molecules. The deals are not charity. They are pipeline replenishment. Washington could not block that flow without telling its own industry to walk away from a third of the world's innovative drug pipeline.
China's Mirror Move
Beijing made a parallel calculation in the same week.
On October 15, China's Ministry of Commerce proposed barring the foreign sale of five biomedical technologies, including cell and gene therapy platforms. The draft list, like the Treasury proposal, explicitly stated that its curbs did not apply to licensing, partnerships, or contract research.
The symmetry is precise. Washington restricted ownership but spared licensing. Beijing restricted the transfer of core technology platforms but spared licensing. Both governments drew the same line: molecules may cross the Pacific, but ownership may not.
The reason is the same on both sides. China has made biopharma a priority industry in its 15th Five-Year Plan. The fastest way to turn a Chinese molecule into revenue is still a Western license, Western clinical trials, and FDA approval. Cutting that off would starve the very companies the plan is meant to build. Beijing's rule aims to stop the uprooting of core technology platforms while allowing companies to earn from licensing those platforms' outputs.
The two governments agree on almost nothing. On this, they agree: the licensing channel remains open.
What the Deal Structure Reveals
The structure of the licensing deals explains why both governments treat them differently from ownership.
A licensing deal transfers the right to develop and commercialize a drug in a specific territory, in exchange for an upfront payment, milestone payments tied to development and regulatory progress, and royalties on sales. The Chinese company retains ownership of the molecule. The American company gets access to it. The transaction is a contract, not a transfer of control.
That structure is acceptable to Washington because it does not give Chinese companies ownership of American assets or American companies ownership of Chinese technology platforms. It is acceptable to Beijing because it generates revenue without transferring the core platform abroad.
The economics work for both sides. The Chinese company gets cash to fund further development and a validation signal from a global partner. The American company gets a late-stage asset without paying for the cost and risk of early-stage discovery. The upfront payment is a fraction of the headline value — typically 6 to 7 percent of the total — but it is the part that funds the next round of research.
The headline number — $139 billion — is mostly milestone payments that may never be paid. The upfront number is real cash. The structure is designed so that the American company pays for what it needs and the Chinese company keeps what it has built.
What the Exemption Means
The Treasury's decision to spare licensing deals is not a signal that Washington has softened its position on Chinese technology. It is a signal that the American pharmaceutical industry's dependence on the Chinese pipeline is too large to restrict without harming the industry itself.
The same week the Treasury proposed investment restrictions, Chinese drugmakers signed another multibillion-dollar licensing deal. The two events were not contradictory. They were two halves of the same policy: restrict ownership, protect access.
For the Chinese biotech companies, the exemption is a validation. The licensing model works. The revenue is real. The global partners are committed. The model does not require American equity investment; it requires American demand for the molecules.
For the American drugmakers, the exemption is a necessity. The patent cliff is approaching. The Chinese pipeline is the most productive source of replacement assets. Restricting licensing would not slow China's biotech industry. It would leave the American industry without a pipeline.
The $139 billion figure is the measure of that dependency. Washington saw the number and drew a line around the deals that produce it. The line was drawn to protect the companies that need China's drugs.
Sources: PharmCube data via Yicai Global (October 16, 2026) and Reuters via Schwab (October 16, 2026); Seoul Economic Daily (October 25, 2026); Nation.com.pk (October 31, 2026); Morgan data via OP-MA (October 24, 2026) and 2026 Q3 biopharma deal analysis via WeChat (October 30, 2026); Xinhua Silk Road CEIS report (September 11, 2026); Treasury Department fact sheet via Asia Times (October 26, 2026) and Pharmaceutical Technology (October 23, 2026); SCMP (September 21 and October 26, 2026); STAT News (October 29, 2026); Reuters via Refinitiv News (October 2, 2026); AstraZeneca-CSPC deal terms via Bernama (January 30, 2026) and Bloomberg (January 30, 2026); BMS-Hengrui deal terms via Yicai (May 12, 2026) and Bloomberg (May 12, 2026); Roche-Hansoh deal terms via American Pharmaceutical Review (October 19, 2026) and BioSpace (October 19, 2026); China Ministry of Commerce draft list via Asia Times (October 26, 2026).
Disclaimer
The information provided in this article is for general informational and educational purposes only. It does not constitute legal, financial, or professional advice. The author and publisher are not responsible for any actions taken based on the content of this article. Readers should consult qualified professionals for advice specific to their situation. All trademarks and references to third-party products, services, or organizations are the property of their respective owners. The performance data and benchmarks discussed are based on specific research studies and may not generalize to all use cases or environments. As of the publication date, the AI landscape continues to evolve rapidly, and readers should verify current information independently.
Limitations
Deal values are potential totals that include milestone payments which may never be paid; upfront cash is reported separately where disclosed.
Figures cover licensing and asset-purchase deals through October 8, 2026, and do not include later transactions.
The Treasury rule is a proposal; final scope and definitions may change before the March 2027 effective date.
Pipeline share and trial-timeline figures come from Chinese regulators and third-party analysts, not from a U.S. government assessment.
Reporting standards differ between Chinese and Western outlets, and figures cited here reflect the primary sources as published.
Market size and shipment estimates vary by methodology; where estimates conflict, the source used is named in the text.
The sectors discussed are changing quickly, and some figures may be revised after publication.
Sources
- PharmCube data via Yicai Global (October 16, 2026) and Reuters via Schwab (October 16, 2026)
- Seoul Economic Daily (October 25, 2026)
- Nation.com.pk (October 31, 2026)
- Morgan data via OP-MA (October 24, 2026) and 2026 Q3 biopharma deal analysis via WeChat (October 30, 2026)
- Xinhua Silk Road CEIS report (September 11, 2026)
- Treasury Department fact sheet via Asia Times (October 26, 2026) and Pharmaceutical Technology (October 23, 2026)
- SCMP (September 21 and October 26, 2026)
- STAT News (October 29, 2026)
- Reuters via Refinitiv News (October 2, 2026)
- AstraZeneca-CSPC deal terms via Bernama (January 30, 2026) and Bloomberg (January 30, 2026)
- BMS-Hengrui deal terms via Yicai (May 12, 2026) and Bloomberg (May 12, 2026)
- Roche-Hansoh deal terms via American Pharmaceutical Review (October 19, 2026) and BioSpace (October 19, 2026)
- China Ministry of Commerce draft list via Asia Times (October 26, 2026).
The information provided in this article is for general informational and educational purposes only. It does not constitute legal, financial, or professional advice. The author and publisher are not responsible for any actions taken based on the content of this article. Readers should consult qualified professionals for advice specific to their situation. All trademarks and references to third-party products, services, or organizations are the property of their respective owners. The performance data and benchmarks discussed are based on specific research studies and may not generalize to all use cases or environments. As of the publication date, the AI landscape continues to evolve rapidly, and readers should verify current information independently.
Limitations: Deal values are potential totals that include milestone payments which may never be paid; upfront cash is reported separately where disclosed.; Figures cover licensing and asset-purchase deals through October 8, 2026, and do not include later transactions.; The Treasury rule is a proposal; final scope and definitions may change before the March 2027 effective date.; Pipeline share and trial-timeline figures come from Chinese regulators and third-party analysts, not from a U.S. government assessment.; Reporting standards differ between Chinese and Western outlets, and figures cited here reflect the primary sources as published.; Market size and shipment estimates vary by methodology; where estimates conflict, the source used is named in the text.; The sectors discussed are changing quickly, and some figures may be revised after publication.